Poxviral Vaccine Retards Progress of Breast, Ovarian Cancers

by Savitha C Muppala on  November 10, 2011 at 10:46 AM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Researchers from National Cancer Institute have found the benefits of recombinant poxviral vaccine on victims of Ovarian and breast cancer.
 Poxviral Vaccine Retards Progress of Breast, Ovarian Cancers
Poxviral Vaccine Retards Progress of Breast, Ovarian Cancers

During the study, 12 patients with breast cancer were administered the vaccine and the research found that the median time to progression was 2.5 months with a median overall survival of 13.7 months.

Among 14 ovarian cancer patients who received the vaccine, the median time to progression was two months with median overall survival of 15.0 months.

Monthly injections of PANVAC vaccines were given to participants expressing tumor-associated antigens (TAA) for carcinoembryonic antigen (CEA) and mucin-1 along with three T-cell costimulatory molecules. Out of the 26 participants, nearly 21 of them had already received three or more rounds of chemotherapy.

"In the study reported here, some patients who had limited tumor burden and whose immune system was not compromised by multiple rounds of chemotherapy seemed to benefit from the vaccine," researchers said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Ovarian Cancer Cancer Vaccination for Children Ovarian Pain Premature Ovarian Failure Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...